COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,790 Articles (22,523 medRxiv, 8,267 bioRxiv)

Most recent first Previous |  Page 905: Articles 9041-9050  | Next

At-Home Testing Study to Assess Risk Factors for Acquisition of SARS-CoV-2 Infection in a Major US Metropolitan Area
Woolley, A. E., Dryden-Peterson, S., Kim, A., Naz-McLean, S., Kelly, C., Laibinis, H. H., Bagnall, J., Livny, J., Ma, P., Orzechowski, M., Shoresh, N., Gabriel, S., Hung, D. T., Cosimi, L. A.
10.1101/2022.02.02.22269258 — Posted: 2022-02-03
SARS-CoV-2 Omicron variant, lineage BA.1, is associated with lower viral load in nasopharyngeal samples compared to Delta variant.
Sentis, C., Billaud, G., Bal, A., Frobert, E., Bouscambert, M., Destras, G., Josset, L., Lina, B., Morfin, F., Gaymard, A., COVID-Diagnosis HCL Study Group
10.1101/2022.02.02.22269653 — Posted: 2022-02-03 Discussion: Onsite
Private Equity Acquisition in Ophthalmology and Optometry: A Time Series Analysis of the Pre-COVID, COVID Pre-Vaccine, and COVID Post-Vaccine Eras
Patil, S. A., Vail, D. G., Cox, J. T., Chen, E. M., Mruthyunjaya, P., Tsai, J. C., Parikh, R.
10.1101/2022.02.03.22270390 — Posted: 2022-02-03
Unraveling the Enzymatic Mechanism of the SARS-CoV-2 RNA-Dependent-RNA-Polymerase. An Unusual Active Site Leading to High Replication Rates.
Bignon, E., Monari, A.
10.1101/2022.02.02.478873 — Posted: 2022-02-03
Development and optimisation of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: evaluation of 5676 phase 1 passed structures
Chiu, W., Verschueren, L., Van den Eynde, C., Buyck, C., De Meyer, S., Jochmans, D., Bojkova, D., Ciesek, S., Cinatl, J., De Jonghe, S., Leyssen, P., Neyts, J., Van Loock, M., Van Damme, E.
10.1101/2022.02.02.478671 — Posted: 2022-02-03
COVID-19 infection enhances susceptibility to oxidative-stress induced parkinsonism
Smeyne, R. J., Eells, J., Chatterjee, D., Byrne, M., Akula, S. M., Sriramula, S., O'Rourke, D., Schmidt, P.
10.1101/2022.02.02.478719 — Posted: 2022-02-03
Doxycycline for the prevention of progression of COVID-19 to severe disease requiring intensive care unit (ICU) admission: a randomized, controlled, open-label, parallel group trial (DOXPREVENT.ICU)
Dhar, R., Kirkpatrick, J., Gilbert, L., Khanna, A., Modi, M. M., Chawla, R. K., Dalal, S., Maturu, V. N., Stern, M., Keppler, O. T., Djukanovic, R., Gadola, S. D.
10.1101/2022.01.30.22269685 — Posted: 2022-02-03
Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine
Hawman, D. W., Meade-White, K., Clancy, C., Archer, J., Hinkley, T., Leventhal, S., Rao, D., Stamper, A., Lewis, M., Rosenke, R., Krieger, K., Randall, S., Khandhar, A. P., Hao, L., Hsiang, T.-Y., Greninger, A. L., Gale, M., Berglund, P., Fuller, D. H., Rosenke, K., Feldmann, H., Erasmus, J.
10.1101/2022.01.31.478520 — Posted: 2022-02-03
Sentinel Cards Provide Practical SARS-CoV-2 Monitoring in School Settings
Cantu, V. J., Sanders, K., Belda-Ferre, P., Salido, R. A., Tsai, R., Austin, B., Jordan, W., Asudani, M., Walster, A., Magallanes, C. G., Valentine, H. D., Majnoonian, A., Wijaya, C., Omaleki, V., Aigner, S., Baer, N. A., Betty, M., Castro-Martinez, A., Cheung, W., De Hoff, P., Eisner, E., Hakim, A., Lastrella, A. L., Lawrence, E. S., Ngo, T. T., Ostrander, R. T., Plascencia, A., Sathe, S., Smoot, E. W., Carlin, A. F., Yeo, G. W., Laurent, L. C., Manlutac, A. L., Fielding-Miller, R., Knight, R.
10.1101/2022.02.01.478759 — Posted: 2022-02-03
Nanoparticle-delivered TLR4 and RIG-I agonists enhance immune response to SARS-CoV-2 subunit vaccine
Atalis, A. M., Keenum, M. C., Pandey, B., Beach, A., Pradhan, P., Vantucci, C. E., Jain, R., Hosten, J., Smith, C., Kramer, L. L., Jimenez, A. C., Armenta-Ochoa, M. A., Frey, D. A., Roy, K.
10.1101/2022.01.31.478507 — Posted: 2022-02-02

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).